May 18, 2018
The U.S. Drug Enforcement Administration on Friday took the rare step of rescinding a suspension order against a Louisiana-based pharmaceutical distributor it had accused of missing suspicious opioid orders, after the company told a Louisiana federal court that the agency relied on shaky methodology.